
|Articles|August 28, 2014
- Head and Neck Cancers (Issue 1)
- Volume 1
- Issue 1
Unmet Needs in the Treatment of Thyroid Cancer
Author(s)Lori J. Wirth, MD
Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses areas of unmet need in the field of thyroid cancer.
Advertisement
Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses areas of unmet need in the field of thyroid cancer.
Read about molecular markers and the diagnosis of thyroid cancer > >
Articles in this issue
almost 12 years ago
Immunotherapy in Head and Neck Cancersalmost 12 years ago
Molecular Markers Emerge in the Diagnosis of Thyroid Canceralmost 12 years ago
Results of the SELECT Trial in Thyroid Canceralmost 12 years ago
Update on Targeted Therapies in Head and Neck Cancersalmost 12 years ago
Multidisciplinary Approach to Head and Neck Cancers May Improve OutcomesAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
3
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
4
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
5






























